{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:49:58Z","timestamp":1791557398454,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41409-026-02927-9","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:09:02Z","timestamp":1785838142000},"page":"1306-1307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From salvage therapy to survivorship: mapping the late effects of autologous stem cell transplantation in autoimmune disease"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-4210","authenticated-orcid":false,"given":"Santhosh","family":"Thyagu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-7645","authenticated-orcid":false,"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2927_CR1","first-page":"497","volume":"16","author":"AM Marmont","year":"1995","unstructured":"Marmont AM, Van Bekkum DW. Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions. Bone Marrow Transpl. 1995;16:497\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2927_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/ard.55.3.149","volume":"55","author":"A Tyndall","year":"1996","unstructured":"Tyndall A, Gratwohl A. Haemopoietic stem and progenitor cells in the treatment of severe autoimmune diseases. Ann Rheum Dis. 1996;55:149\u201351. https:\/\/doi.org\/10.1136\/ard.55.3.149.","journal-title":"Ann Rheum Dis"},{"key":"2927_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/sj.bmt.1700727","volume":"19","author":"A Tyndall","year":"1997","unstructured":"Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 1997;19:643\u20135. https:\/\/doi.org\/10.1038\/sj.bmt.1700727.","journal-title":"Bone Marrow Transpl"},{"key":"2927_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2009.013458","volume":"95","author":"D Farge","year":"2010","unstructured":"Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010;95:284\u201392. https:\/\/doi.org\/10.3324\/haematol.2009.013458.","journal-title":"Haematologica"},{"key":"2927_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/s0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498\u2013506. https:\/\/doi.org\/10.1016\/s0140-6736(11)60982-3.","journal-title":"Lancet"},{"key":"2927_CR6","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. Jama. 2014;311:2490\u20138. https:\/\/doi.org\/10.1001\/jama.2014.6368.","journal-title":"Jama"},{"key":"2927_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018;378:35\u201347. https:\/\/doi.org\/10.1056\/nejmoa1703327.","journal-title":"N Engl J Med"},{"key":"2927_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1212\/wnl.0000000000001329","volume":"84","author":"GL Mancardi","year":"2015","unstructured":"Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84:981\u20138. https:\/\/doi.org\/10.1212\/wnl.0000000000001329.","journal-title":"Neurology"},{"key":"2927_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","volume":"321","author":"RK Burt","year":"2019","unstructured":"Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321:165\u201374. https:\/\/doi.org\/10.1001\/jama.2018.18743.","journal-title":"JAMA"},{"key":"2927_CR10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/s0140-6736(16)30169-6","volume":"388","author":"HL Atkins","year":"2016","unstructured":"Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388:576\u201385. https:\/\/doi.org\/10.1016\/s0140-6736(16)30169-6.","journal-title":"Lancet"},{"key":"2927_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","volume":"80","author":"T Kalincik","year":"2023","unstructured":"Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, et al. Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol. 2023;80:702\u201313. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1184.","journal-title":"JAMA Neurol"},{"key":"2927_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","volume":"106","author":"J Henes","year":"2021","unstructured":"Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 2021;106:375\u201383. https:\/\/doi.org\/10.3324\/haematol.2019.230128.","journal-title":"Haematologica"},{"key":"2927_CR13","doi-asserted-by":"publisher","first-page":"e1215","DOI":"10.1212\/wnl.0000000000011461","volume":"96","author":"G Boffa","year":"2021","unstructured":"Boffa G, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2021;96:e1215\u201326. https:\/\/doi.org\/10.1212\/wnl.0000000000011461.","journal-title":"Neurology"},{"key":"2927_CR14","unstructured":"Kirill K, Raffaella G, Manuela B, Myriam L, Riccardo S, Montserrat R, et al. Late Complications After Autologoous HSCT for Autoimmune Diseases: A retrospective survey from the Autoimmune Diseases Working Party (ADWP), Transplant Complications Working Party (TCWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2026 (In Press)."},{"key":"2927_CR15","unstructured":"BEAT-MS. Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) [Internet]. ClinicalTrials.gov.NLM Identifier: NCT04047628. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04047628."},{"key":"2927_CR16","unstructured":"RAM-MS. Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)[Internet]. ClinicalTrials.gov.NLM Identifier: NCT03477500. Sponsor: Haukeland University Hospital; Information provided by Haukeland University Hospital (Responsible Party). Last update posted 06\/25\/2025. Available from: https:\/\/clinicaltrial.gov\/study\/NCT03477500."},{"key":"2927_CR17","doi-asserted-by":"publisher","first-page":"e083582","DOI":"10.1136\/bmjopen-2023-083582","volume":"14","author":"G Brittain","year":"2024","unstructured":"Brittain G, Petrie J, Duffy KEM, Glover R, Hullock K, Papaioannou D, et al. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. BMJ Open. 2024;14:e083582. https:\/\/doi.org\/10.1136\/bmjopen-2023-083582.","journal-title":"BMJ Open"},{"key":"2927_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02927-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:59:51Z","timestamp":1791554391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02927-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2927"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02927-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}